Related references
Note: Only part of the references are listed.Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420
Tricia M. Tan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Acute Pancreatitis Associated with Liraglutide
Phillip H Lee et al.
ANNALS OF PHARMACOTHERAPY (2011)
The utility of animal models to evaluate novel anti-obesity agents
Steven P. Vickers et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans
Akila De Silva et al.
CELL METABOLISM (2011)
The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY)
R. E. Steinert et al.
CLINICAL NUTRITION (2011)
New Drug Targets for the Treatment of Obesity
A. G. Powell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3-36
Melisande L. Addison et al.
ENDOCRINOLOGY (2011)
Cutting-edge technologies in colon-targeted drug delivery systems
Mayur M. Patel
EXPERT OPINION ON DRUG DELIVERY (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
John B. Buse et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Long-Acting Lipidated Analogue of Human Pancreatic Polypeptide Is Slowly Released into Circulation
Kathrin Bellmann-Sickert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
DPP-IV-resistant, long-acting oxyntomodulin derivatives
Alessia Santoprete et al.
JOURNAL OF PEPTIDE SCIENCE (2011)
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects
Robert E. Steinert et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
Krystyna Tatarkiewicz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Association of Pancreatitis with Glucagon-Like Peptide-I Agonist Use
Sarah L. Anderson et al.
ANNALS OF PHARMACOTHERAPY (2010)
(D-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
Barry D. Kerr et al.
BIOCHEMICAL PHARMACOLOGY (2010)
PYY3-36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
Benjamin C. T. Field et al.
DIABETES (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
D. Russell-Jones
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
Y-L Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway et al.
LANCET (2010)
Depression-like phenotype following chronic CB1 receptor antagonism
Chad E. Beyer et al.
NEUROBIOLOGY OF DISEASE (2010)
Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways
Amanda Sainsbury et al.
NEUROPEPTIDES (2010)
Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones
Zaza Kokrashvili et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2009)
Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
Jacqueline A. Koehler et al.
DIABETES (2009)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Maralyn R. Druce et al.
ENDOCRINOLOGY (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI)
James R. C. Parkinson et al.
NEUROIMAGE (2009)
Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats
Roger D. Reidelberger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2008)
Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: A proof-of-concept study in healthy subjects
C. Beglinger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
No evidence of an additive inhibitory feeding effect following PP and PYY3-36 administration
N. M. Neary et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
William J. Thomsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake
Carel W. le Roux et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2008)
A novel long-acting selective neuropeptide y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents
Astrid A. Ortiz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1
Hyeung-Jin Jang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats
Prasanth K. Chelikani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice
Lynn B. DeCarr et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
Birgitte Sloth et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Low-dose pancreatic polypeptide inhibits food intake in man
David R. Jesudason et al.
BRITISH JOURNAL OF NUTRITION (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures
C. M. Mack et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively
NM Neary et al.
ENDOCRINOLOGY (2005)
Effect of peptide YY3-36 on food intake in humans
L Degen et al.
GASTROENTEROLOGY (2005)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
PK Chelikani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice
Y Shechter et al.
FEBS LETTERS (2005)
Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats
PK Chelikani et al.
ENDOCRINOLOGY (2005)
Comparison of the Atkins, Ornish, Weight watchers, and Zone diets for weight loss and heart disease risk reduction
ML Dansinger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects
M Kidron et al.
DIABETIC MEDICINE (2004)
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
LL Baggio et al.
GASTROENTEROLOGY (2004)
Peripheral oxyntomodulin reduces food intake and body weight gain in rats
CL Dakin et al.
ENDOCRINOLOGY (2004)
Gastrointestinal satiety signals - III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide
S Stanley et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)
Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse
BG Challis et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Oxyntomodulin suppresses appetite and reduces food intake in humans
MA Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Inhibition of food intake in obese subjects by peptide YY3-36
RL Batterham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pancreatic polypeptide reduces appetite and food intake in humans
RL Batterham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Gut hormone PYY3-36 physiologically inhibits food intake
RL Batterham et al.
NATURE (2002)
Oxyntomodulin inhibits food intake in the rat
CL Dakin et al.
ENDOCRINOLOGY (2001)
Oral delivery of biologically active parathyroid hormone
A Leone-Bay et al.
PHARMACEUTICAL RESEARCH (2001)
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
FR de Fonseca et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Share Paper
